For people with type 2 diabetes

The risk of diabetic kidney disease is not the same for everyone.

INNOVATIO-ND2 is a predictive test based on protein biomarkers. From one blood sample, it identifies up to 4 years in advance who will lose kidney function and how fast. eGFR and ACR show how the kidney is today; INNOVATIO-ND2 shows where it is heading.

CPT 0385U · Covered by Traditional Medicare, MCS (Advantage and commercial) and MMM (Advantage and Vital)

Kidney drawn as a network of molecules, highlighting the biomarkers ApoA4, CD5L and IGFBP3

One test, three answers

A test that reads as predictive, not just diagnostic.

1 · Diagnosis

Is diabetic kidney disease already present?

A result above 30% indicates kidney disease is present, even when ACR and eGFR look normal.

2 · 4-year prognosis

Will eGFR fall by 30% or more?

Classifies the risk of an eGFR decline of 30% or more over the next 4 years as low, medium or high.

3 · Speed

Fast or slow progression?

When kidney damage is present, it separates slow, medium and fast progressors without years of serial eGFR.

What each test tells you

What each test tells you
TestCurrent kidney functionFuture kidney functionRate of decline
INNOVATIO-ND2YesYesYes
Urine albumin-to-creatinine ratio (ACR)YesNoNo
Estimated glomerular filtration rate (eGFR)YesNoNo

Information for everyone

Physicians

How to read the result and act

Risk levels, recommended management, candidates and how to order.

Go to Physicians →
Patients

Know your risk in time

What diabetic kidney disease is, how often to test and how to ask for it.

Go to Patients →
Clinical laboratories

Inside the assay

Assay type, algorithm variables, turnaround and availability.

Go to Laboratories →

Where to get tested

56 laboratories in 32 towns in Puerto Rico have experience drawing the sample, plus every Laboratorios Borinquen branch.